OrthoPediatrics Corp.

NASDAQ•KIDS

CEO: Mr. Mark C. Throdahl

Sector: Healthcare

Industry: Medical - Devices

Listing Date: 2017-10-13

OrthoPediatrics Corp., a medical device company, engages in designing, developing, and marketing anatomically appropriate implants, instruments, and specialized braces for children with orthopedic conditions in the United States and internationally. The company offers pediatric trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity; and sports medicine and other products. Its products comprise PediLoc, PediPlates, cannulated screws, PediFlex nail, PediNail, PediLoc Tibia, ACL Reconstruction System, Locking Cannulated Blade, Locking Proximal Femur, Spica Tables, RESPONSE Spine, BandLoc, Pediguard, Pediatric Nailing Platform | Femur, Devise Rail, Orthex, The Fassier-Duval Telescopic Intramedullary System, SLIMTM Nail, The GAP Nail, The Free Gliding SCFE Screw System, GIROTM Growth Modulation System, PNP Tibia System, ApiFix Mid-C System, and Mitchell Ponseti. The company serves pediatric orthopedic market, as well as pediatric orthopedic surgeons and caregivers. OrthoPediatrics Corp. was founded in 2006 and is headquartered in Warsaw, Indiana.

Contact Information

2850 Frontier Drive, Warsaw, IN, 46582, United States

574-268-6379

www.orthopediatrics.com

Market Cap

$446.92M

P/E (TTM)

-10.6

Dividend Yield

52W High

$26.40

52W Low

$15.28

52W Range

23%

Rank65Top 96.0%

1.6

F-Score

Modified Piotroski Analysis

Based on 10-year fundamentals

Weak • 1.6 / 9 points

Scoring Range (0-9)

8-9: Excellent Value

6-7: Strong Fundamentals

4-5: Average Quality

0-3: Weak Performance

Data Period: 2016-2025

Financial Dashboard

Q4 2025 Data

Revenue

$61.61M+0.00%

4-Quarter Trend

EPS

-$0.43+0.00%

4-Quarter Trend

FCF

$9.75M+0.00%

4-Quarter Trend

2025 Annual Earnings Highlights

Key Highlights

Strong Annual Revenue Growth Total revenue reached 236.3M USD, up 15% from 204.7M USD in 2024, driven by strong performance in trauma and scoliosis segments.

Scoliosis Segment Expansion Scoliosis revenue reached 66.0M USD, up 20% from 55.2M USD in 2024, reflecting increased sales of RESPONSE and 7D technology systems.

Trauma Segment Performance Trauma and deformity revenue reached 166.3M USD, up 15% from 145.1M USD in 2024, representing 70% of total annual global revenue.

Risk Factors

Persistent Operating Losses Net loss widened to 39.6M USD in 2025 from 37.8M USD in 2024, reflecting ongoing challenges in achieving and sustaining future profitability.

Regulatory Compliance Risks Extensive FDA and international regulations, including MDR certification, impose significant compliance costs and potential delays in product clearances or market access.

Third-Party Sales Reliance Reliance on independent sales agencies for 56% of global revenue creates risks if agencies fail to promote products or terminate business relationships.

Product Liability Exposure Potential product liability claims inherent in medical device sales could result in significant litigation costs, reputational damage, and decreased product demand.

Outlook

Strategic Market Expansion Plans to deepen penetration in Brazil and Germany, leveraging new warehouses and legal entities to drive international growth and market share.

R&D Investment Focus Commitment to launch at least one new surgical system and multiple product line extensions annually to address unmet pediatric orthopedic needs.

Clinic Network Growth Continued focus on selective clinic acquisitions and greenfield expansion to strengthen O&P service offerings and improve patient access to specialized care.

Peer Comparison

Revenue (TTM)

EHAB

$1.06B

+2.4%

VREX

$854.40M

+4.1%

AVNS

$701.20M

+1.9%

Gross Margin (Latest Quarter)

SMLR

91.5%

+0.1pp

LAB

83.5%

-3.2pp

TMCI

80.6%

-1.1pp

Key Metrics

Symbol	Market Cap	P/E (TTM)	ROE (TTM)	Debt to Assets
CGEM	$880.83M	-4.1	-45.5%	0.6%
EHAB	$689.84M	-149.9	-0.8%	42.8%
SRDX	$614.51M	-34.8	-15.6%	19.2%

Long-Term Trends

Last 4 Quarters

Revenue

Net Income

Operating Cash Flow

4Q Revenue CAGR

5.5%

Steady Growth

4Q Net Income CAGR

N/M

Profitability Shift

Cash Flow Stability

25%

Cash Flow Needs Attention

Deep Research

Next earnings:May 5, 2026

EPS:-

Revenue:-

Financials

Earnings Calls

Reports

News

Income Statement

Balance Sheet

Cash Flow Statement

Ratios

% Chg.

Income Statement	LTM

No Data